**The federal marijuana rescheduling process centers on a bifurcated April 2026 DOJ/DEA order that immediately moved FDA-approved cannabis products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act, while leaving recreational and unlicensed cannabis in Schedule I.** This action followed a December 2025 executive order directing expedited review. A separate administrative hearing on broader rescheduling to Schedule III, including adult-use markets, ran from June 29 to July 15, 2026; post-hearing briefs closed in August, and the administrative law judge’s recommendation remains pending with no statutory deadline for a final DEA rule. Trader probabilities for near-term broader rescheduling reflect uncertainty over the ALJ outcome, potential legal challenges, and the limited scope of the existing medical carve-out. Key upcoming factors include any final rulemaking and related implementation or litigation developments.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado$802,588 Vol.
31 dez 2026
30 de setembro
2%
31 de dezembro
26%
$802,588 Vol.
30 de setembro
$262 Vol.
2%
31 de dezembro
$192,755 Vol.
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The federal marijuana rescheduling process centers on a bifurcated April 2026 DOJ/DEA order that immediately moved FDA-approved cannabis products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act, while leaving recreational and unlicensed cannabis in Schedule I.** This action followed a December 2025 executive order directing expedited review. A separate administrative hearing on broader rescheduling to Schedule III, including adult-use markets, ran from June 29 to July 15, 2026; post-hearing briefs closed in August, and the administrative law judge’s recommendation remains pending with no statutory deadline for a final DEA rule. Trader probabilities for near-term broader rescheduling reflect uncertainty over the ALJ outcome, potential legal challenges, and the limited scope of the existing medical carve-out. Key upcoming factors include any final rulemaking and related implementation or litigation developments.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado Aberto: Feb 7, 2026, 5:04 PM ET
Volume
$802,588Data de Término
1 jan 2027Mercado Aberto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The federal marijuana rescheduling process centers on a bifurcated April 2026 DOJ/DEA order that immediately moved FDA-approved cannabis products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act, while leaving recreational and unlicensed cannabis in Schedule I.** This action followed a December 2025 executive order directing expedited review. A separate administrative hearing on broader rescheduling to Schedule III, including adult-use markets, ran from June 29 to July 15, 2026; post-hearing briefs closed in August, and the administrative law judge’s recommendation remains pending with no statutory deadline for a final DEA rule. Trader probabilities for near-term broader rescheduling reflect uncertainty over the ALJ outcome, potential legal challenges, and the limited scope of the existing medical carve-out. Key upcoming factors include any final rulemaking and related implementation or litigation developments.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$802,588Data de Término
1 jan 2027Mercado Aberto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**The federal marijuana rescheduling process centers on a bifurcated April 2026 DOJ/DEA order that immediately moved FDA-approved cannabis products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act, while leaving recreational and unlicensed cannabis in Schedule I.** This action followed a December 2025 executive order directing expedited review. A separate administrative hearing on broader rescheduling to Schedule III, including adult-use markets, ran from June 29 to July 15, 2026; post-hearing briefs closed in August, and the administrative law judge’s recommendation remains pending with no statutory deadline for a final DEA rule. Trader probabilities for near-term broader rescheduling reflect uncertainty over the ALJ outcome, potential legal challenges, and the limited scope of the existing medical carve-out. Key upcoming factors include any final rulemaking and related implementation or litigation developments.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions